Scholars Central

Conference abstractPublished 7 Dec 2018

Bispecific anti-17 A/F nanoantibody - The first nanoantibody in treatment of psoriasis.

Authors: Danka Svecova

Comenius University in Bratislava, Slovak Republic

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Nanoantibodies are a new class of antibody -derived biologics. Nanotechnology was originally developed following the discovery and identification that Camelidae possess fully functional antibody that consists of heavy chain only and lack light chain. They form the basis of a new generation of therapeutic molecules â??nanoantibodiesâ?�. The anti-IL-17 A/F nanoantibody neutralizes the pro-inflammatory cytokines IL-17A and IL-17 F, which have been implicated in the pathogenesis of psoriasis. This multicentric, phase I and II, randomized, double -blind, placebo-controlled study investigated multiple ascending doses of anti-IL-17 A/F nanoantibody in patients with moderate-to-severe psoriasis vulgaris. The 33 patients were evaluated; mean age 44,8 year, male/female ratio 29/4. Body surface area (BSA) â?¥10%, Psoriasis Area and Severity Index (PASI)â?¥12, and static Physician´s Global Assessment (sPGA) â?¥3 were evaluated. Patients received 30, 60, 120 or 240 mg anti-IL-17 A/F nanoantibody or placebo every two weeks subcutaneously for 6 weeks. Primary endpoints were safety, tolerability, immunogenicity, and pharmacokinetics (demonstrated on 2017 Annual Meeting of American Academy of Dermatology). Secondary endpoints were pharmacodynamics, efficacy and histologic analysis. On day 85, 6 weeks after the last dose of the drug, PASI 75 was achieved in 7/8 patients (88%) receiving 30 or 60 mg, 8/8 (100%) receiving 120 mg, and 9/9 (100%) receiving 240 mg of drug. PASI 90 was achieved in 4/8 (50%), 7/8 (88%) and 9/9 (100%) patients receiving 30 mg, 60 mg, 120 mg or 240 mg, respectively. PASI 100 was achieved in 1/8 (13%), 2/8 (25%), 4/8 (50%) and 5/9 (56%) patients receiving 30 mg, 60 mg, 120 mg or 240 mg, respectively. No placebo-treated patient achieved PASI 75, 90 or 100 on Day 85. Improved PASI scores were seen 7 days post-first dose in all 4 cohorts. Biopsy assessment of skin lesion showed complete reversal of disease pathology in majority of patients in high dose groups. Conclusion: Anti-IL-17 A/F bispecific nanoantibody is well tolerated and effective in patients with moderate-to severe psoriasis and was associated with clear skin improvement in all indices of psoriasis studied. The trial was supported by Merck/EMD Serano.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Oncology Translational Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Oncology Translational Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Danka Svecova”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels